Filtered By:
Specialty: Pharmaceuticals
Cancer: Cancer
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 41 results found since Jan 2013.
OSU Wexner Medical Center set to launch Brain and Spine Institute in former James space
Ohio State University and Wexner Medical Center trustees will be asked this week to approve a $14.3 million specialty Brain and Spine Institute in the former home of James Cancer Hospital and Solove Research Institute.
The medical center's board votes Wednesday on the $1.1 million design phase of the renovation, creating 80 to 90 beds for neurological care and adding specialty units such as for dementia, trauma, stroke and rehabilitation, according to its agenda. http://trustees.osu.edu/assets/files/meeting-materials/01-2015/Med%20Center.pdf…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 26, 2015 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news
Low-Dose Aspirin Recommended at Ages 50 to 69
An influential federal panel recommended daily low-dose aspirin for men and women ages 50 to 69 to prevent heart attacks, stroke and colorectal cancer, setting off what is expected to be an intense debate given the drug’s side effects, including higher risk of bleeding.
Source: WSJ.com: Health - September 15, 2015 Category: Pharmaceuticals Tags: FREE Source Type: news
Getting Social in the Real World
Although it would be facetious to say that social media has reached a tipping point into ubiquity, it is only relatively recently that it has been used by pharma to collect and analyze patient data. This use of social media may only be in its infancy but as a quick and inexpensive way to gather large-scale, real-world data it is growing rapidly.Technology always outstrips the glacial pace that industry moves at, but this ‘sudden’ move creates a sharp learning curve for many pharma companies. Issues around regulation and resources will hinder some, while others will fail to see the value of ‘social health’.Popular s...
Source: EyeForPharma - March 6, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
Bristol-Myers raises forecasts on strong sales of stroke and cancer drugs
The US pharmaceutical company beat expectations on earnings and revenue in the first quarter
Source: FT.com - Drugs and Healthcare - April 25, 2019 Category: Pharmaceuticals Source Type: news
Statins May Be Beneficial After Radiation to Thorax, Head, Neck
WEDNESDAY, June 19, 2019 -- For cardiac patients with thorax and head or neck cancer, statin use after radiation therapy is associated with a significant reduction in stroke incidence and a trend toward reduced cardiovascular and cerebrovascular...
Source: Drugs.com - Pharma News - June 19, 2019 Category: Pharmaceuticals Source Type: news
With Comorbidities, Less Than Six Hours of Sleep Ups Risk for Early Death
FRIDAY, Oct. 4, 2019 -- Middle-aged adults with high blood pressure, type 2 diabetes, heart disease, or stroke could be at higher risk for cancer and early death when sleeping less than six hours per day, according to a study published online Oct. 2...
Source: Drugs.com - Pharma News - October 4, 2019 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Aspirin use to prevent 1st heart attack or stroke should be curtailed, US panel says
The U.S. panel also plans to retreat from its 2016 recommendation to take baby aspirin for the prevention of colorectal cancer, guidance that was groundbreaking at the time. The panel said that more recent data had raised questions about the putative benefits for cancer, and that more research was needed.
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Survey: Noncommunicable Diseases Still Underestimated, Only 59% View Diabetes As Very Harmful
Gallup also found that of those interviewed only 83% considered cancer, 72% considered heart disease and stroke, and 51% considered lung disease to be "very harmful. ”
Source: Forbes.com Healthcare News - October 17, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink pharma Source Type: news
